{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-095744","form_type":"8-K","ticker":"ACET","cik":"0001720580","company_name":"Adicet Bio, Inc.","filed_at":"2024-08-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.256428+00:00","generated_at":"2026-05-31T09:45:41.487545+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Adicet Bio Q2 net loss $29.9M; expands ADI-001 into three more autoimmune indications","bullets":["Net loss $29.9M ($0.33/share) vs $32.4M ($0.75) in Q2 2023; cash $224.1M, sufficient into H2 2026.","FDA cleared IND for ADI-001 in SLE, SSc, AAV; Fast Track for LN; enrollment starts Q3 2024 with data H1 2025.","FDA cleared IND for ADI-270 in RCC with Fast Track Designation; Phase 1 to start Q4 2024, data H1 2025.","R&D expenses $25.9M, down from $28.4M; G&A $6.9M, up from $6.5M.","MCL enrollment ongoing in ADI-001 Phase 1 GLEAN study; clinical update Q4 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-095744","json":"https://secwatch.observer/filing/0000950170-24-095744.json","markdown":"https://secwatch.observer/filing/0000950170-24-095744.md","text":"https://secwatch.observer/filing/0000950170-24-095744.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1720580/000095017024095744/0000950170-24-095744-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1720580/000095017024095744/acet-20240813.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T09:45:41.487545+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}